INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...

Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...

Danny Keating, President and CEO of the Company, commented: “After an extensive shortlisting process, we are delighted to have partnered with a group with world class hydrometallurgical engineering ...

* Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2 * Strongbridge Biopharma Plc - on schedule to commence ...

* Indivior Plc - 24-week study met its primary and key secondary endpoints for both dosage regimens of RBP-6000 * Indivior - Clinical data from phase 3 study also showed outcomes with RBP-6000 are ...

They cite financial security as their top life concern. More than seven in 10 young adults in Asia (71%) who responded to a Prudential plc study choose clear financial planning over spontaneity, as ...